Prognosis and outcome of stem cell transplantation for mantle cell lymphoma.

about

Prognosis and outcome of stem cell transplantation for mantle cell lymphoma.

Item

http://www.wikidata.org/entity/Q38532268

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Prognosis and outcome of stem cell transplantation for mantle cell lymphoma.

@en

type

Item

label

Prognosis and outcome of stem cell transplantation for mantle cell lymphoma.

@en

prefLabel

Prognosis and outcome of stem cell transplantation for mantle cell lymphoma.

@en

P1476

Prognosis and outcome of stem cell transplantation for mantle cell lymphoma.

@en

P2093

Felipe Suarez

http://www.w3.org/2001/XMLSchema#string

Morgane Cheminant

http://www.w3.org/2001/XMLSchema#string

Richard Delarue

http://www.w3.org/2001/XMLSchema#string

Stephen Robinson

http://www.w3.org/2001/XMLSchema#string

Steven Le Gouill

http://www.w3.org/2001/XMLSchema#string

Vincent Ribrag

http://www.w3.org/2001/XMLSchema#string

P2860

Improvement of Overall Survival in Advanced Stage Mantle Cell Lymphoma

Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma.

Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma.

A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma

Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study.

Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma

Transplantation for mantle cell lymphoma: is it the right thing to do?

Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study.

Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial.

Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma.

P304

493-504

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/17474086.2015.1047759

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Olivier Hermine

P577

2015-06-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26091558

http://www.w3.org/2001/XMLSchema#string